Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania.

Lancet (London, England) - 13 Oct 2001

Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, Hills E, Watkins W

Abstract excerpt

BACKGROUND: Resistance to the affordable malaria treatments chloroquine and pyrimethamine-sulfadoxine is seriously impeding malaria control through treatment in east Africa. We did an open, alternate drug allocation study to assess the efficacy of chlorproguanil-dapsone in the treatment of falciparum malaria clinically resistant to pyrimethamine-sulfadoxine. METHODS: Children younger than 5 years with non-severe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimalarials
Share to Dapsone
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Malaria, Falciparum

Share to Proguanil

Share to Pyrimethamine

Share to Sulfadoxine

Share to Tanzania

Source

Identifiers

PMID: 11675058
DOI: 10.1016/S0140-6736(01)06344-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania.PMID 11675058Read ↗

Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?Semantic proximity Read ↗

Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites.Semantic proximity Read ↗

Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategies.Semantic proximity Read ↗

Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.Semantic proximity Read ↗

A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria.Semantic proximity Read ↗

Chloroquine and Sulfadoxine–Pyrimethamine Resistance in Sub-Saharan Africa—A ReviewSemantic proximity Read ↗

Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi.Semantic proximity Read ↗

Design and selection of drug properties to increase the public health impact of next-generation seasonal malaria chemoprevention: a modelling studySemantic proximity Read ↗

Sulphadoxine/pyrimethamine versus amodiaquine for treating uncomplicated childhood malaria in Gabon: a randomized trial to guide national policy.Semantic proximity Read ↗

Low-dose treatment with sulfadoxine-pyrimethamine combinations selects for drug-resistant Plasmodium falciparum strains.Semantic proximity Read ↗

High levels of sulphadoxine-pyrimethamine resistance Pfdhfr-Pfdhps quintuple mutations: a cross sectional survey of six regions in Tanzania.Semantic proximity Read ↗

High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.